Skye Bioscience Inc.(US:SKYE) Prnewswire·2026-01-06 15:55Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Skye Biosciences, Inc. due to allegations of misleading statements regarding the effectiveness of its drug nimacimab, which led to significant financial losses for investors [2][4]. Group 1: Legal Investigation - Faruqi & Faruqi is encouraging investors who suffered losses in Skye to contact them to discuss their legal options [1]. - A federal securities class action has been filed against Skye, with a deadline of January 16, 2026, for investors to seek the role of lead plaintiff [2][6]. - The firm has a history of recovering hundreds of millions of dollars for investors since its founding in 1995 [3]. Group 2: Allegations Against Skye - The complaint alleges that Skye and its executives violated federal securities laws by making false statements about nimacimab's effectiveness and overstating its clinical and commercial prospects [4]. - On October 6, 2025, Skye announced that nimacimab did not achieve its primary endpoint in a clinical study, leading to a 60% drop in stock price, closing at $1.90 per share [5]. Group 3: Call for Information - Faruqi & Faruqi is also seeking information from whistleblowers, former employees, and shareholders regarding Skye's conduct [7].